186 related articles for article (PubMed ID: 19907215)
1. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?
Martin-Blondel G; Cuzin L; Delobel P; Cuvinciuc V; Dumas H; Alvarez M; Massip P; Marchou B
AIDS; 2009 Nov; 23(18):2545-6. PubMed ID: 19907215
[No Abstract] [Full Text] [Related]
2. Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome.
Martin-Blondel G; Bauer J; Uro-Coste E; Biotti D; Averseng-Peaureaux D; Fabre N; Dumas H; Bonneville F; Lassmann H; Marchou B; Liblau RS; Brassat D
Acta Neuropathol; 2015 Mar; 129(3):463-5. PubMed ID: 25589222
[No Abstract] [Full Text] [Related]
3. Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.
Shahani L; Shah M; Tavakoli-Tabasi S
BMJ Case Rep; 2015 Jun; 2015():. PubMed ID: 26063110
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
Giacomini PS; Rozenberg A; Metz I; Araujo D; Arbour N; Bar-Or A;
N Engl J Med; 2014 Jan; 370(5):486-8. PubMed ID: 24476450
[No Abstract] [Full Text] [Related]
5. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effect of maraviroc in semen: a case report.
Pasquier C; Moinard N; Sauné K; Daudin M; Trancart S; Massip P; Izopet J; Bujan L
Antivir Ther; 2012; 17(5):933-6. PubMed ID: 22297568
[TBL] [Abstract][Full Text] [Related]
7. High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.
Stork L; Brück W; Bar-Or A; Metz I
Acta Neuropathol; 2015 Mar; 129(3):467-8. PubMed ID: 25604548
[No Abstract] [Full Text] [Related]
8. Images in HIV/AIDS. Fatal progressive multifocal leukoencephalopathy: still a problem in the era of highly active antiretroviral therapy.
Cole J; Aboulafia DM
AIDS Read; 2009 Mar; 19(3):110-2. PubMed ID: 19334327
[No Abstract] [Full Text] [Related]
9. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy.
Portilla J; Boix V; Román F; Reus S; Merino E
J Infect; 2000 Sep; 41(2):182-4. PubMed ID: 11023768
[TBL] [Abstract][Full Text] [Related]
10. Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
Moyle G; Rajicic N; Goodrich J; Mayer H; Valdez H
AIDS; 2009 Jul; 23(12):1613. PubMed ID: 19622911
[No Abstract] [Full Text] [Related]
11. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.
Stepanyuk O; Chiang TS; Dever LL; Paez SL; Smith SM; Perez G; Eng RH
AIDS; 2009 Sep; 23(14):1911-3. PubMed ID: 19584703
[TBL] [Abstract][Full Text] [Related]
12. Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Kwon HY; Han YJ; Im JH; Baek JH; Lee JS
Int J STD AIDS; 2019 Oct; 30(11):1131-1135. PubMed ID: 31533530
[No Abstract] [Full Text] [Related]
13. Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy.
Teófilo E; Gouveia J; Brotas V; da Costa P
AIDS; 1998 Mar; 12(4):449. PubMed ID: 9520183
[No Abstract] [Full Text] [Related]
14. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918
[No Abstract] [Full Text] [Related]
15. When and how to use maraviroc in HIV-infected patients.
Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
[No Abstract] [Full Text] [Related]
16. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.
Delobel P; Raymond S; Mavigner M; Cazabat M; Alvarez M; Marchou B; Massip P; Izopet J
AIDS; 2010 Jun; 24(9):1382-4. PubMed ID: 20559045
[No Abstract] [Full Text] [Related]
17. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.
Hall CD; Dafni U; Simpson D; Clifford D; Wetherill PE; Cohen B; McArthur J; Hollander H; Yainnoutsos C; Major E; Millar L; Timpone J
N Engl J Med; 1998 May; 338(19):1345-51. PubMed ID: 9571254
[TBL] [Abstract][Full Text] [Related]
18. [Case of highly active anti-retroviral therapy-induced immune reconstitution inflammatory syndrome in AIDS-related progressive multifocal leukoencephalopathy].
Imamura E; Yamashita H; Fukuhara T; Sawa H; Nagashima K; Kuwabara M; Tokinobu H
Rinsho Shinkeigaku; 2007 Oct; 47(10):650-6. PubMed ID: 18095498
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV agents. Maraviroc in treatment-experienced PHAs.
TreatmentUpdate; 2006; 18(4):5. PubMed ID: 17205654
[No Abstract] [Full Text] [Related]
20. Immune reconstitution inflammatory syndrome in an HIV-infected patient with disseminated coccidioidomycosis.
Lin AY; Chun V; Dhamija A; Bordin-Wosk T; Kadakia A
Int J STD AIDS; 2019 Aug; 30(9):923-926. PubMed ID: 31159717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
